Stock News

RBC Capital Positive On ImmunoGen (IMGN) with $9.0 Target; Banc Funds Co Has Decreased Its Old Line Bancshares (OLBK) Holding

Among 9 analysts covering Immunogen (NASDAQ:IMGN), 6 have Buy rating, 1 Sell and 2 Hold. Therefore 67% are positive. Immunogen has $24 highest and $500 lowest target. $14’s average target is 55.38% above currents $9.01 stock price. Immunogen had 27 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of ImmunoGen, Inc. (NASDAQ:IMGN) earned “Buy” rating by Jefferies on Friday, September 8. The stock of ImmunoGen, Inc. (NASDAQ:IMGN) has “Sector Perform” rating given on Friday, April 29 by RBC Capital Markets. The firm earned “Outperform” rating on Wednesday, July 29 by Oppenheimer. Canaccord Genuity maintained the stock with “Buy” rating in Friday, November 3 report. The stock has “Buy” rating by RBC Capital Markets on Tuesday, August 29. The rating was maintained by Jefferies on Friday, November 3 with “Buy”. Jefferies maintained the stock with “Buy” rating in Tuesday, October 10 report. The company was maintained on Monday, June 26 by Jefferies. Cowen & Co maintained the shares of IMGN in report on Friday, July 28 with “Hold” rating. The stock has “Hold” rating by Cowen & Co on Tuesday, August 29.

Banc Funds Co Llc decreased Old Line Bancshares Inc. (OLBK) stake by 7.84% reported in 2017Q3 SEC filing. Banc Funds Co Llc sold 38,747 shares as Old Line Bancshares Inc. (OLBK)’s stock declined 5.42%. The Banc Funds Co Llc holds 455,630 shares with $12.76M value, down from 494,377 last quarter. Old Line Bancshares Inc. now has $387.63 million valuation. The stock increased 0.31% or $0.09 during the last trading session, reaching $30.99. About 26,788 shares traded. Old Line Bancshares, Inc. (NASDAQ:OLBK) has risen 54.07% since February 8, 2017 and is uptrending. It has outperformed by 37.37% the S&P500.

Investors sentiment decreased to 1.16 in 2017 Q3. Its down 0.04, from 1.2 in 2017Q2. It worsened, as 16 investors sold ImmunoGen, Inc. shares while 48 reduced holdings. 38 funds opened positions while 36 raised stakes. 87.70 million shares or 19.45% more from 73.42 million shares in 2017Q2 were reported. Endurant Ltd Partnership has invested 0.18% in ImmunoGen, Inc. (NASDAQ:IMGN). Twin Focus Capital Ltd Liability Company reported 113,216 shares or 0.45% of all its holdings. Envestnet Asset Management owns 25,826 shares or 0% of their US portfolio. Art Ltd Liability Co accumulated 166,036 shares or 0.06% of the stock. Millennium Management Ltd invested 0.04% in ImmunoGen, Inc. (NASDAQ:IMGN). New York-based Clearbridge has invested 0.08% in ImmunoGen, Inc. (NASDAQ:IMGN). Ubs Asset Mngmt Americas invested in 0% or 50,239 shares. Raymond James And holds 457,754 shares. First Manhattan Company holds 0% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN) for 3,046 shares. Metropolitan Life Insur accumulated 0% or 65,678 shares. Fny Managed Accounts Limited Liability Com holds 2,400 shares or 0.02% of its portfolio. Schwab Charles Invest Management Inc invested in 441,445 shares. Hightower Ltd Liability Co stated it has 0% in ImmunoGen, Inc. (NASDAQ:IMGN). Massachusetts-based Ngam Advsr L P has invested 0.02% in ImmunoGen, Inc. (NASDAQ:IMGN). Goldman Sachs Gp holds 0% or 131,570 shares.

Analysts await ImmunoGen, Inc. (NASDAQ:IMGN) to report earnings on February, 16. They expect $-0.07 earnings per share, up 82.05% or $0.32 from last year’s $-0.39 per share. After $-0.37 actual earnings per share reported by ImmunoGen, Inc. for the previous quarter, Wall Street now forecasts -81.08% EPS growth.

Since September 13, 2017, it had 0 insider buys, and 2 insider sales for $262,957 activity. 37,050 shares were sold by BARROWS CRAIG, worth $252,457. The insider Berkenblit Anna sold $10,500.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company has market cap of $1.19 billion. The firm develops its products using its antibody-drug conjugate technology. It currently has negative earnings. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML.

The stock decreased 0.11% or $0.01 during the last trading session, reaching $9.01. About 2.65 million shares traded. ImmunoGen, Inc. (NASDAQ:IMGN) has declined 3.49% since February 8, 2017 and is downtrending. It has underperformed by 20.19% the S&P500.

Since October 30, 2017, it had 1 insider purchase, and 2 sales for $116,584 activity. 3,475 shares were sold by BURNETT JOSEPH E, worth $104,250 on Monday, October 30. The insider DENT JAMES F sold $31,653. On Monday, January 29 MANUEL GAIL D bought $19,319 worth of Old Line Bancshares, Inc. (NASDAQ:OLBK) or 620 shares.

Banc Funds Co Llc increased County Bancorp Inc. stake by 86,995 shares to 299,330 valued at $9.00 million in 2017Q3. It also upped Sussex Bancorp (NASDAQ:SBBX) stake by 40,000 shares and now owns 564,767 shares. York Traditions Bank was raised too.

Investors sentiment decreased to 0.92 in Q3 2017. Its down 1.28, from 2.2 in 2017Q2. It turned negative, as 8 investors sold OLBK shares while 28 reduced holdings. 7 funds opened positions while 26 raised stakes. 5.48 million shares or 6.24% more from 5.16 million shares in 2017Q2 were reported. Victory Mngmt has invested 0% in Old Line Bancshares, Inc. (NASDAQ:OLBK). Macquarie has invested 0% in Old Line Bancshares, Inc. (NASDAQ:OLBK). First Tru Advisors LP holds 22,462 shares or 0% of its portfolio. Lsv Asset holds 0% in Old Line Bancshares, Inc. (NASDAQ:OLBK) or 25,411 shares. Fj Cap Mngmt Ltd Liability Corporation has invested 2.24% in Old Line Bancshares, Inc. (NASDAQ:OLBK). Maltese Capital Mngmt Limited Co has 26,700 shares for 0.06% of their portfolio. Stifel Fincl Corp reported 37,397 shares or 0% of all its holdings. 16,540 were reported by Martingale Asset Management L P. Vanguard Group Incorporated Incorporated stated it has 0% of its portfolio in Old Line Bancshares, Inc. (NASDAQ:OLBK). 8,774 were accumulated by Rhumbline Advisers. Voya Investment Mngmt Limited Com accumulated 7,251 shares. State Common Retirement Fund reported 9,300 shares. Bessemer Group owns 0% invested in Old Line Bancshares, Inc. (NASDAQ:OLBK) for 9,000 shares. Bankshares Of Mellon holds 0% or 33,639 shares in its portfolio. 359,639 were accumulated by Endeavour Cap.

Leave a Reply

Your email address will not be published. Required fields are marked *